TIMI 12

TIMI 12 evaluated the safety and efficacy of the oral GP IIb/IIa inhibitor sibrafiban for the treatment of patients with a recent acute coronary syndrome.

DOWNLOAD SLIDE SET (PDF)

Key Study Publications

Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation. 1998;97:340-9. Abstract